Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma. Pigne T, Levy M, Ducharme O, Dutriaux C, et al. Melanoma Res 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.

Read + Share

Amedeo Smart

Independent Medical Education

Pigne T, Levy M, Ducharme O, Dutriaux C, et al. Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma. Melanoma Res 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
PMID: 36919691